Abstract
High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements or both, commonly called double-hit lymphoma (DHL), is an aggressive B-cell lymphoma that is molecularly distinct from diffuse large B-cell lymphoma (DLBCL) and is associated with poor outcomes. Recent advances in the molecular classification of DLBCL have identified distinct subsets, including genetic signatures which correlate with DHL and survival. DHL with concomitant TP53 mutation appears to be associated with a very poor prognosis. Standard chemo-immunotherapy is not an effective treatment for these patients and personalized, innovative strategies are needed. In this review, we summarize recent advances in the subclassification of DLBCL, with a focus on DHL. We also incorporate early, promising clinical trial data using CAR T and targeted therapies. Rationally designed clinical trials for DLBCL are needed to advance the care of patients with DHL and other adverse risk DLBCL subgroups.
Original language | English (US) |
---|---|
Pages (from-to) | 1034-1044 |
Number of pages | 11 |
Journal | Leukemia and Lymphoma |
Volume | 63 |
Issue number | 5 |
DOIs | |
State | Published - 2022 |
Externally published | Yes |
Keywords
- CAR T
- Double-hit lymphoma
- double expressor lymphoma
- high-grade B-cell lymphoma
- targeted therapy
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research